You are here

Bazedoxafine

11-December-2014

In October 2014, the Committee for Medicinal Products for Human Use licensed Duavive, (conjugated oestrogens 0.45 mg/ bazedoxifene 20 mg) modified-release tablets, for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom progestins are contraindicated. Bazedoxafine is an oestrogen receptor antagonist which reduces the oestrogen-induced risk of endometrial hyperplasia.

E-Alert

Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.


Share


News

Commentaries by Editor Prof. Jim Thornton